Normosang (Human Hemin)

Normosang is used to treat acute porphyric attacks by supplying exogenous heme and reducing toxic precursor buildup.

• Acute intermittent porphyria: alleviates neurovisceral symptoms by lowering aminolevulinic acid and porphobilinogen levels.
• Hereditary coproporphyria: shortens the duration of abdominal pain and neurological manifestations during an acute episode.
• Variegate porphyria: helps control severe attacks by suppressing the hepatic heme synthesis pathway.

• Human Hemin provides exogenous heme that restores the intracellular heme pool, leading to feedback inhibition of aminolevulinic acid synthase (ALAS1), the rate‑limiting enzyme of the hepatic heme biosynthetic pathway. By decreasing ALAS1 activity, the accumulation of neurotoxic precursors such as aminolevulinic acid and porphobilinogen is reduced, mitigating the clinical manifestations of acute porphyric attacks. The restored heme also supports normal function of cytochrome P450 enzymes involved in drug metabolism.

Normosang may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Phlebitis at the infusion site: pain, redness, and swelling may occur.
• Mild fever or chills: transient temperature rise during or shortly after infusion.
• Nausea or vomiting: gastrointestinal upset commonly reported.
• Headache: mild to moderate intensity, often resolves spontaneously.

Serious or Rare Side Effects

• Acute hemolytic anemia: rapid destruction of red blood cells requiring monitoring.
• Severe allergic reaction (anaphylaxis): respiratory distress, hypotension, and urticaria demand immediate treatment.
• Renal impairment or hemoglobinuria: reduced kidney function and dark urine may indicate hemoglobin release.

Before using Normosang, clinicians should consider several precautionary measures to ensure patient safety and product integrity.

• Indication verification: confirm the patient is experiencing an acute porphyric attack before administration.
• Baseline labs: obtain liver function tests, renal function, and complete blood count prior to infusion.
• Infusion rate: administer slowly as recommended to reduce risk of phlebitis and systemic reactions.
• Monitoring: observe vital signs and for signs of hypersensitivity during and after infusion.
• Contraindications: avoid use in patients with known hypersensitivity to hemin or porphyria‑related hepatic failure.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines, and the nature of the interaction determines the level of clinical attention required.

Major Interactions (Avoid)

• Porphyrinogenic drugs: agents such as barbiturates, sulfonamides, and certain antiepileptics may exacerbate porphyria and should be avoided.
• Iron supplements: high intravenous iron can compete with hemin for binding sites, reducing efficacy.

Moderate Interactions (Monitor Closely)

• Cytochrome P450 substrates: hemin may induce hepatic enzymes, potentially lowering plasma levels of drugs metabolized by CYP1A2, CYP2C9, or CYP3A4.
• Anticoagulants: hemin can affect coagulation parameters; monitor INR or aPTT when used with warfarin or heparin.
• Vitamin D analogues: concurrent use may require monitoring of calcium levels due to potential renal effects.